He Tingshan, Li Jing, Ouyang Yanling, Lv Guotao, Ceng Xiaofeng, Zhang Zhiqiao, Ding Jianqiang
Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong, China.
Department of Pathology, Shunde Hospital, Southern Medical University, Shunde, Guangdong, China.
J Clin Transl Hepatol. 2020 Jun 28;8(2):113-119. doi: 10.14218/JCTH.2019.00053. Epub 2020 Apr 28.
FibroScan is used to determine liver stiffness and controlled attenuation parameter (referred to as CAP) scores in patients, including those with chronic hepatitis B (CHB). We used FibroScan to detect the incidence of fatty liver and fibrosis in CHB patients, and to assess the correlation of FibroScan measurements with blood chemistry tests. CHB patients enrolled in this study were divided independently for three separate analyses (of fibrosis, cirrhosis, and fatty liver) based on FibroScan results. Basic information, blood chemistry test results, liver fibrosis parameters, and FibroScan results were collected. T-tests and Pearson's analyses were used to analyze the correlations between FibroScan liver stiffness measurement/CAP values and liver function, blood fat, uric acid metabolite, fibrosis, and hepatitis B virus load. A total of 2266 CHB patients were enrolled in the study and divided into three groups: non-significant and significant fibrosis; non-cirrhosis and early cirrhosis; and non-fatty and fatty liver. Spearman's statistical analyses showed that liver stiffness measurement or CAP values correlated with sex (=0.137), age (=0.119),glutamic-pyruvic transaminase (=0.082), glutamic-oxaloacetic transaminase (=-0.172), gamma-glutamyltransferase (=0.225), albumin (=0.150), globulin (=-0.107), total bilirubin (=-0.132), direct bilirubin (=-0.145), white blood cell count (=0.254), hemoglobin (=0.205), platelets (=0.206), total cholesterol (=0.214), high density lipoprotein (=-0.243), low density lipoprotein (=0.255), apolipoprotein B (=0.217), hyaluronic acid (=-0.069), laminin (=-0.188), procollagen type IV (=-0.067)and hepatitis B viral DNA load (=-0.216). FibroScan is a non-invasive device that can detect the occurrence of fatty liver or liver fibrosis in CHB patients.
FibroScan用于测定患者的肝脏硬度和受控衰减参数（简称为CAP）评分，包括慢性乙型肝炎（CHB）患者。我们使用FibroScan检测CHB患者中脂肪肝和肝纤维化的发生率，并评估FibroScan测量值与血液生化检测的相关性。本研究纳入的CHB患者根据FibroScan结果独立分为三组进行三项单独分析（肝纤维化、肝硬化和脂肪肝）。收集基本信息、血液生化检测结果、肝纤维化参数和FibroScan结果。采用t检验和Pearson分析来分析FibroScan肝脏硬度测量值/CAP值与肝功能、血脂、尿酸代谢产物、肝纤维化及乙肝病毒载量之间的相关性。共有2266例CHB患者纳入本研究，并分为三组：无显著和显著肝纤维化；无肝硬化和早期肝硬化；无脂肪肝和脂肪肝。Spearman统计分析表明，肝脏硬度测量值或CAP值与性别（=0.137）、年龄（=0.119）、谷丙转氨酶（=0.082）、谷草转氨酶（=-0.172）、γ-谷氨酰转移酶（=0.225）、白蛋白（=0.150）、球蛋白（=-0.107）、总胆红素（=-0.132）、直接胆红素（=-0.145）、白细胞计数（=0.254）、血红蛋白（=0.205）、血小板（=0.206）、总胆固醇（=0.214）、高密度脂蛋白（=-0.243）、低密度脂蛋白（=0.255）、载脂蛋白B（=0.217）、透明质酸（=-0.069）、层粘连蛋白（=-0.188）、IV型前胶原（=-0.067）及乙肝病毒DNA载量（=-0.216）相关。FibroScan是一种无创设备，可检测CHB患者中脂肪肝或肝纤维化的发生情况。
